Supplementary Table S5 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

Abstract

<p>Supplementary Table S5: Novel pathogenic mutations discovered in cfDNA. List of novel pathogenic mutations found in cfDNA samples that were not detected in the bulk tumour tissue by whole exome sequencing. For each mutation, both the variant allele frequency (VAF), median fragment size and total fragment count for ALT and REF reads (only available for SNVs), and inferred status (somatic or CHIP mutation) are shown.</p>